PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds, PetCare Rx, and PetMeds brands. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.

PetMed Express looks like a company with a very cheap valuation, but against the backdrop of a weak operating base and deteriorating balance sheet dynamics. The P/S ratio at 0.23 is noticeably below the industry median, which formally supports the undervaluation thesis; however, P/E and P/FCF do not provide solid support because of zero or incorrectly reflected values for earnings and free cash flow. P/B is slightly above the median, which means that even with low revenue, the market does not see a strong margin of safety in the capital base. Liquidity remains weak: a current ratio of 0.84 and a quick ratio of 0.47 are below comfortable levels, and their decline over the years points to a shrinking working capital buffer. There is no long-term debt, which is a positive, but this does not offset the overall deterioration in balance sheet quality and the reduction in cash from $41 million to $13 million. Profitability looks extremely weak: ROE, ROA, ROI, operating margin, and net margin are all zero, while gross margin of 27.22% is below the industry median and has also weakened compared with earlier periods. Revenue declined from $51 million to $41 million, which for a retail/consumer model is a concerning sign of pressure on demand or competition. Net income remains positive, but at $2 million versus stronger figures in the past, while operating income in the latest period has effectively dropped to zero. Shareholders’ equity and net worth are shrinking, indicating a gradual erosion of the financial cushion. The dividend yield of 2.39% looks supportive for investors, but given weak earnings and declining liquidity, its sustainability does not appear certain. Overall, the fundamentals justify a cautious approach: the valuation is indeed cheap, but this reflects weak growth, low profitability, and a deteriorating balance sheet. For the target price, only a modest negative adjustment is appropriate, since upside rerating is limited by execution risks and the absence of a convincing turnaround in operating metrics.

PetMed Express, Inc.

Сильный индекс, значительно вырос

Слабый индекс, значительно упал. Рынок не поддерживает быков.

Weak index, significantly down. The market does not support the bulls.

Слабый индекс, незначительно вырос

PETS’s cheap valuation on revenue does not offset weak liquidity, declining revenue and profitability; the dividend and lack of debt only partially mitigate the risks.

(RTTNews) - PetMed Express, Inc., the parent company of PetCareRx (PETS), announced the appointment of Tamar Elkeles as an independent director and Chair of the Compensation and Human Capital Committee, effective September 17, 2026.
PetMeds is a direct-to-consumer pet healthcare company.
Tamar Elkeles has more than three decades of experience as an executive, board member, and strategic advisor across the technology, enterprise software and human capital industries.
She currently serves as a Senior Advisor at East Wind Advisors, an Advisor at 444 Capital and a Venture Partner at Emerge Capital, and she sits on the boards of Brightline Interactive and Open Sesame.
From 1992 to 2015, she served as Chief Learning and Talent Officer at Qualcomm, during which the company's revenue grew from $100 million to more than $25 billion and its global workforce expanded from 700 to 35,000 employees.
Tamar Elkeles' appointment follows the company's recent executive leadership transition, in which Jeff Willard was appointed Chief Executive Officer and President, succeeding Leslie C.G. Campbell, who served as Interim CEO and President and as Chair of the Board.
PETS has traded between $1.57 and $4.10 over the last year. The stock closed Monday's trade at $1.60, down 0.62%.
PETS is up 1.87% to $1.63 in after-hours trading.
For more such biotechstock newsvisit www.rttnews.com.

PetMeds Appoints Tamar Elkeles As Independent Director

(RTTNews) - PetMed Express, Inc. (PETS), doing business as PetMeds and parent company of PetCareRx, announced the appointment of Jeff Willard as Chief Executive Officer and President and as a member of the Board of Directors, effective September 28, 2026.
Willard succeeds Leslie C.G. Campbell, who has served as Interim Chief Executive Officer and President since August 2025 and will retire as Chair of the Board and step down as a director on September 28, 2026.
Willard brings more than 25 years of leadership experience across consumer and e-commerce companies, with a background in driving growth, improving operations and developing brands.
He most recently served as CEO of Stewart-MacDonald (StewMac), a global e-commerce provider of guitar tools and parts.
Previously, Willard served as Chief Growth Officer and Chief Marketing Officer of Casper, President of Healthy Lifestyle Brands and CEO of Zac Brown Collective.
Earlier in his career, he held senior executive positions at Simmons Bedding Company, Harman International, Coleman, Helen of Troy and Lexmark International.
Following his appointment, Willard will focus on operational execution and the company's efforts to return to sustainable profitability and growth.
As part of the board leadership transition, the company appointed Justin Mennen, currently Lead Independent Director and Chair of the Corporate Governance and Nominating Committee, to succeed Campbell as Chair of the Board, effective September 28, 2026.
Peter Batushansky, a current member of the Corporate Governance and Nominating Committee, will succeed Mennen as Committee Chair on the same date.
Mennen will step down as Committee Chair but will remain a member of the committee and continue serving on the PetMeds Board.
Mennen currently serves as Chief Information and Technology Officer of Shake Shack Inc. and has been a member of the PetMeds Board since June 2024.
Campbell will remain with PetMeds as a full-time Strategic Advisor for 60 days following Willard's arrival to support business continuity and the leadership transition.
Campbell has served on the PetMeds Board since 2018 and became Board Chair in January 2024. She also served as Interim Chief Executive Officer and President since August 2025.
PetMeds, founded in 1996, operates as a direct-to-consumer pet healthcare company and online pharmacy licensed across all 50 states.
Through PetMeds and its PetCareRx subsidiary, the company offers pharmaceuticals, compounded medications, over-the-counter supplements and nutrition products for dogs, cats and horses.
PETS has traded between $1.57 and $4.10 over the past year. The stock closed Wednesday's trading at $4.10, down 1.23%. In pre-market trading, the stock is at $1.61, up 1.24%.

PetMeds CEO Transition: Jeff Willard To Succeed Leslie Campbell

Skip to main content
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.
© 2026, Nasdaq, Inc. All Rights Reserved.
My Quotes

PetMed Express (PETS) Q1 2027 Earnings Call Transcript

PetMed Express, Inc. PETS reported first-quarter fiscal 2027 results, with both the top and bottom lines missing the Zacks Consensus Estimate. Sales also declined year over year, while loss per share narrowed.
PETS’ Q1 Key Performance Metrics
PetMed Express reported a loss of 28 cents per share compared with $1.65 per share in the prior-year quarter. The improvement in net loss was primarily driven by the absence of the prior-year goodwill and trade name impairment charges, along with lower general and administrative and advertising expenses. These benefits were partly offset by lower gross profit.
PetMed Express, Inc. Price, Consensus and EPS Surprise
Net sales declined 19.9% year over year to $41 million from $51.2 million, primarily due to continued softness in prescription medication sales, partly offset by lower consumer promotional usage.
Recurring net sales, which include AutoShip and membership-related revenue, accounted for 61.5% of total gross sales, up from 57.6% in the prior-year quarter. The company acquired approximately 70,000 new customers during the quarter while lowering its customer acquisition cost by 15% year over year to $60 from $71. The improvement reflected more efficient advertising and media spending, including the elimination of unproductive media programs.
PetMed Express’ Margin & Cost Performance
Gross profit declined 21.3% year over year to $11.3 million from $14.4 million, mainly due to lower manufacturer rebates as a percentage of sales, partly offset by lower net freight costs per order.
General and administrative expenses decreased 13.5% year over year to $11.2 million from $12.9 million, reflecting lower professional fees, share-based compensation and severance costs. Advertising expenses fell 30.2% year over year to $4.2 million from $6 million, primarily due to lower gross media spending and the elimination of unproductive media.
Total operating expenses declined 63.8% year over year to $17.6 million from $48.5 million, largely because the prior-year period included a $27.3 million goodwill and intangible-asset impairment charge.
The company reported an operating loss of $6.2 million compared with $34.1 million in the year-ago quarter. Adjusted EBITDA loss widened to $3.4 million from $2.7 million in the prior-year period.
PetMed Express’ Growth Initiatives
PetMeds continues to focus on improving customer acquisition while lowering acquisition costs. In July, the company launched its co-branded online pharmacy offering with Rural King, giving customers across more than 150 stores in 17 states access to pet medications, prescription food, preventatives and AutoShip services through a platform powered by PetMeds.
As its first large-scale white-label pharmacy program, the partnership is designed to broaden PetMeds’ customer reach, bring in-store shoppers online and create additional revenue streams by utilizing its pharmacy infrastructure, licensed pharmacists and e-commerce capabilities. Management also said it expects to extend the white-label offering to additional partners in the near future.
PETS’ Financial Position & Capital Allocation
PetMed Express ended the quarter with cash and cash equivalents of $13.1 million compared with $21.4 million at March 31, 2026. The company had no debt as of June 30, 2026.
Net cash used in operating activities was $7.7 million compared with $12.3 million in the prior-year period. Capital expenditures totaled roughly $0.6 million, down from $1.3 million a year earlier.
The company entered into a definitive agreement to sell its headquarters and distribution center buildings in Delray Beach, FL, through a sale-leaseback transaction valued at $37 million. It will lease back the portion of the property housing its offices and Florida distribution center under a 10-year lease with renewal options. The transaction is expected to close within approximately 120 days from the date of the definitive agreement, subject to due diligence, lease negotiations and other customary closing conditions.
What to Expect From PetMed Express in the Future?
This Zacks Rank #3 (Hold) company has strengthened its operating foundation through financial, operational and commercial improvements implemented over the past 12 months, along with strategic partnerships and a more disciplined approach to expense management and capital allocation. Management plans to build on these improvements as the company works toward sustainable profitability and long-term shareholder value.
By leveraging its modernized technology and operational initiatives, the company aims to build on its service capabilities while improving customer retention. It is also leveraging its pet pharmacy expertise and infrastructure to strengthen B2B relationships through membership programs and white-label fulfillment services, helping extend its reach to more customers.
The company’s shares have lost 9.5% over the past three months against the industry’s growth of 2.8%.
Stocks to Consider
Some better-ranked stocks have been discussed below:
Central Garden & Pet Company CENT produces and distributes various products for the lawn and garden and pet supplies markets in the United States. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for CENT’s current financial-year sales implies a decline of 4.8%, and the same for earnings implies growth of 7% from the year-ago reported numbers. CENT delivered a trailing four-quarter earnings surprise of 41.8%, on average.
Globe E-Online Ltd. GLBE provides a direct-to-consumer cross-border e-commerce platform in Israel, the United Kingdom, the United States and internationally. At present, GLBE carries a Zacks Rank of 2.
The Zacks Consensus Estimate for GLBE’s current fiscal-year sales and earnings indicates growth of 29.8% and 187.2%, respectively, from the year-ago figures. GLBE delivered a trailing four-quarter earnings surprise of 12.6%, on average.
Amazon.com Inc. AMZN engages in the retail sale of consumer products, advertising, and subscription services through online and physical stores in North America and internationally. At present, Amazon carries a Zacks Rank of 2.
The consensus estimate for Amazon’s current fiscal-year sales and earnings implies growth of 15.7% and 82.2%, respectively, from the year-ago figures. AMZN delivered a trailing four-quarter earnings surprise of 5.5%, on average.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y

eBay (EBAY) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5.96%. A quarter ago, it was expected that this e-commerce company would post earnings of $1.58 per share when it actually produced earnings of $1.66, delivering a surprise of +5.06%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
eBay, which belongs to the Zacks Internet - Commerce industry, posted revenues of $3.13 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.85%. This compares to year-ago revenues of $2.73 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
eBay shares have added about 25.8% since the beginning of the year versus the S&P 500's gain of 13%.
What's Next for eBay?
While eBay has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for eBay was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.43 on $2.99 billion in revenues for the coming quarter and $6.08 on $12.2 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Commerce is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
PetMed (PETS), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13.
This pet pharmacy company is expected to post quarterly earnings of $0.12 per share in its upcoming report, which represents a year-over-year change of +135.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
PetMed's revenues are expected to be $51.68 million, up 1% from the year-ago quarter.
Should You Invest in eBay Inc. (EBAY)?
Before you invest in eBay Inc. (EBAY), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
eBay Inc. (EBAY) : Free Stock Analysis Report
PetMed Express, Inc. (PETS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

eBay (EBAY) Q2 Earnings and Revenues Top Estimates

(RTTNews) - PetMed Express, Inc. (PETS), a pet healthcare company, announced on Tuesday the receipt of a cash-only, non-binding, conditional proposal from SilverCape Investments Limited to acquire all outstanding shares of the company at $3.00 per share.
PetMed previously received a similar proposal from SilverCape in December 2025, for the acquisition of the company's common shares at $4.00 per share. However, after extensive discussions, SilverCape announced the withdrawal of the proposal in April 2026, citing a refusal to sign a non-disclosure agreement containing a customary standstill provision.
The company stated that the Board had not reached any conclusion on the latest proposal and remains focused on overseeing core operations and maximizing long-term value for shareholders.
PETS closed Tuesday's trade at $1.92, up 5.49%. In the pre-market, shares are trading down 1.04% to $1.90.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PetMed Express Receives $3 Per Share Buyout Proposal From SilveCape

(RTTNews) - Monday, Singapore-based SilverCape Investments Limited announced a revised proposal to acquire all outstanding shares of PetMed Express, Inc. (PETS) for $3.00 per share in cash.
In an open letter, SilverCape stated that the revised price reflects PetMed's continued deterioration and represents a superior alternative for PetMed stockholders to the company's current value-destructive course. It further urged the Board to act before the remaining value of the company is eroded and destroyed.
Also, the letter highlighted that as PetMed is no longer viable as a public company due to its dismal quarterly and fiscal year reports, rapidly depleting cash balance, and a lack of effective leadership.
SilverCape ended the letter stating that it also welcomes other third-party alternatives that offer stockholders superior value and would be supportive of PetMed running a structured and independent process to consider those alternatives.
In the pre-market hours, PetMed's stock is trading at $2.3399, up 32.43 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

SilverCape Investments Announces Revised Proposal To Buy PetMed Express For $3/Share

The NASDAQ 100 Pre-Market Indicator is up 244.55 to 29,362.79. The total Pre-Market volume is currently 184,407,727 shares traded.
The following are the most active stocks for the pre-market session:
NN, Inc. (NNBR) is +1.31 at $4.07, with 39,045,126 shares traded. NNBR's current last sale is 67.83% of the target price of $6.
PetMed Express, Inc. (PETS) is +0.5187 at $2.28, with 11,248,104 shares traded. PETS's current last sale is 74.1% of the target price of $3.075.
Comcast Corporation (CMCSA) is +5.38 at $28.55, with 7,275,313 shares traded. CMCSA's current last sale is 89.22% of the target price of $32.
iShares Bitcoin Trust ETF (IBIT) is +0.35 at $34.20, with 5,642,567 shares traded. This represents a 4.14% increase from its 52 Week Low.
Defiance Daily Target 2x Short RKLB ETF (RKLZ) is -0.7895 at $3.22, with 4,971,217 shares traded. This represents a 92.84% increase from its 52 Week Low.
ProShares UltraPro QQQ (TQQQ) is +2.8798 at $74.71, with 3,448,105 shares traded. This represents a 100.19% increase from its 52 Week Low.
Nokia Corporation (NOK) is -0.2 at $12.81, with 3,030,183 shares traded. As reported by Zacks, the current mean recommendation for NOK is in the "buy range".
Redwire Corporation (RDW) is +0.74 at $11.67, with 1,467,467 shares traded. As reported by Zacks, the current mean recommendation for RDW is in the "buy range".
BitMine Immersion Technologies, Inc. (BMNR) is +0.3 at $13.86, with 968,541 shares traded. As reported by Zacks, the current mean recommendation for BMNR is in the "buy range".
BlackBerry Limited (BB) is -0.02 at $11.38, with 864,751 shares traded., following a 52-week high recorded in prior regular session.
Alibaba Group Holding Limited (BABA) is +1.09 at $95.90, with 745,362 shares traded. As reported by Zacks, the current mean recommendation for BABA is in the "buy range".
Virgin Galactic Holdings, Inc. (SPCE) is +0.13 at $3.08, with 687,138 shares traded. SPCE's current last sale is 99.35% of the target price of $3.1.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Most Active for Jun 29, 2026 : NNBR, PETS, CMCSA, IBIT, RKLZ, TQQQ, NOK, RDW, BMNR, BB, BABA, SPCE

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

PetMed Express (PETS) Q4 2026 Earnings Transcript

PDD Holdings Inc. Sponsored ADR (PDD) came out with quarterly earnings of $3.08 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $3.2 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +61.26%. A quarter ago, it was expected that this company would post earnings of $2.49 per share when it actually produced earnings of $1.56, delivering a surprise of -37.35%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
PDD Holdings Inc. Sponsored ADR, which belongs to the Zacks Internet - Commerce industry, posted revenues of $14.52 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.15%. This compares to year-ago revenues of $13.36 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
PDD Holdings Inc. Sponsored ADR shares have added about 31.1% since the beginning of the year versus the S&P 500's gain of 10%.
What's Next for PDD Holdings Inc. Sponsored ADR?
While PDD Holdings Inc. Sponsored ADR has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for PDD Holdings Inc. Sponsored ADR was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #5 (Strong Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.15 on $14.95 billion in revenues for the coming quarter and $8.70 on $59.53 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Commerce is currently in the bottom 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, PetMed (PETS), is yet to report results for the quarter ended June 2025.
This pet pharmacy company is expected to post quarterly loss of $0.06 per share in its upcoming report, which represents a year-over-year change of -133.3%. The consensus EPS estimate for the quarter has been revised 42.9% lower over the last 30 days to the current level.
PetMed's revenues are expected to be $58.71 million, down 13.6% from the year-ago quarter.
Should You Invest in PDD Holdings Inc. Sponsored ADR (PDD)?
Before you invest in PDD Holdings Inc. Sponsored ADR (PDD), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	Apr 26	May 26	Jun 26	Jul 26	Sep 26	TTM	Median
P/E	—	0.00	0.00	0.00	0.00	0.00	17.39
Price/Sales	—	0.26	0.24	0.23	—	0.23	0.66
P/B	—	1.12	1.81	—	—	1.81	1.68
P/FCF	0.00	—	0.00	0.00	—	0.00	12.74

Indicator	Apr 26	May 26	Jun 26	Jul 26	Sep 26	TTM	Median
ROE	—	—	0.00	—	—	0.00	15.36
ROA	—	—	0.00	—	—	0.00	4.97
ROI	—	—	—	—	—	0.00	8.47
Net Worth	—	0.05	0.04	0.04	—	0.04	0.82
Quick Ratio	—	—	0.47	—	—	0.47	0.85
Current Ratio	—	—	—	—	—	0.84	1.38

Indicator	Apr 26	May 26	Jun 26	Jul 26	Sep 26	TTM	Median
Net Profit Margin	—	—	0.00	—	—	0.00	5.79
Operating Margin	—	—	0.00	—	—	0.00	8.36
Gross Margin	—	—	27.22	—	—	27.22	39.57
Return on tangible equity	—	—	0.00	—	—	0.00	22.12

Indicator	Apr 26	May 26	Jun 26	Jul 26	Sep 26	TTM	Median
EPS	—	—	-0.19	-0.19	—	-0.19	0.52
EPS Forecast	—	—	-0.18	-0.18	—	-0.18	0.51
Revenue	—	—	41.00M	—	—	41.00M	193.00M
Gross Profit	—	—	11.00M	—	—	11.00M	—
EBITDA	—	—	—	—	—	24.00M	—

PetMed Express, Inc.

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue